ATC Group: N06BA11 Dexmethylphenidate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06BA11 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics
4 N06BA Centrally acting sympathomimetics
5 N06BA11

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 15 mg

Active ingredients in N06BA11

Active Ingredient Description
Dexmethylphenidate

Dexmethylphenidate is a CNS stimulant. It is the more pharmacologically active d-enantiomer of racemic methylphenidate. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known.

Related product monographs

Title Information Source Document Type  
FOCALIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Estonia (EE)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.